Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
Clinical trial NCT05716009 · TERMINATED
Trial details
- NCT number
- NCT05716009
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-20
- Primary completion
- 2025-05-05
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.